Preventing thrombosis in a COVID-19 patient by combinatorial therapy with nafamostat and heparin during extracorporeal membrane oxygenation.
Shunichi DoiYoshihiro J AkashiMumon TakitaHideki YoshidaDaiki MorikawaYuki IshibashiTakumi HigumaShigeki FujitaniPublished in: Acute medicine & surgery (2020)
Combination therapy with nafamostat and heparin can prevent circuit thrombosis during ECMO. However, bleeding can still develop with this combination therapy during ECMO.
Keyphrases
- combination therapy
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome
- pulmonary embolism
- venous thromboembolism
- coronavirus disease
- growth factor
- sars cov
- respiratory failure
- case report
- atrial fibrillation
- mechanical ventilation
- stem cells
- intensive care unit
- bone marrow
- respiratory syndrome coronavirus
- replacement therapy
- smoking cessation